WO2022260667A1 - Oral dosage forms of ibrutinib - Google Patents
Oral dosage forms of ibrutinib Download PDFInfo
- Publication number
- WO2022260667A1 WO2022260667A1 PCT/US2021/036712 US2021036712W WO2022260667A1 WO 2022260667 A1 WO2022260667 A1 WO 2022260667A1 US 2021036712 W US2021036712 W US 2021036712W WO 2022260667 A1 WO2022260667 A1 WO 2022260667A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- oral dosage
- ibrutinib
- weight percent
- amount
- Prior art date
Links
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 title claims abstract description 88
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 title claims abstract description 88
- 229960001507 ibrutinib Drugs 0.000 title claims abstract description 88
- 239000006186 oral dosage form Substances 0.000 title claims abstract description 80
- 239000011230 binding agent Substances 0.000 claims abstract description 32
- 239000002535 acidifier Substances 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 25
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 21
- 239000000661 sodium alginate Substances 0.000 claims abstract description 21
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 21
- 239000007884 disintegrant Substances 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 201000005787 hematologic cancer Diseases 0.000 claims abstract description 11
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims abstract description 11
- 239000000314 lubricant Substances 0.000 claims abstract description 11
- 239000000945 filler Substances 0.000 claims abstract description 10
- 239000004094 surface-active agent Substances 0.000 claims abstract description 9
- 208000009329 Graft vs Host Disease Diseases 0.000 claims abstract description 5
- 208000024908 graft versus host disease Diseases 0.000 claims abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- 239000002775 capsule Substances 0.000 claims description 44
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 35
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 34
- 235000002906 tartaric acid Nutrition 0.000 claims description 34
- 239000011975 tartaric acid Substances 0.000 claims description 34
- 229960001367 tartaric acid Drugs 0.000 claims description 30
- 239000008363 phosphate buffer Substances 0.000 claims description 20
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 19
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 17
- 235000019359 magnesium stearate Nutrition 0.000 claims description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 17
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 16
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 15
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 12
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 12
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 12
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 12
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 12
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 229940068977 polysorbate 20 Drugs 0.000 claims description 11
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 6
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 6
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 6
- 229960004106 citric acid Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 abstract description 41
- 239000000203 mixture Substances 0.000 description 36
- 239000002253 acid Substances 0.000 description 28
- 238000009472 formulation Methods 0.000 description 24
- 239000003814 drug Substances 0.000 description 21
- 229940079593 drug Drugs 0.000 description 20
- 238000004090 dissolution Methods 0.000 description 17
- 239000003002 pH adjusting agent Substances 0.000 description 17
- 239000008186 active pharmaceutical agent Substances 0.000 description 14
- 229920000136 polysorbate Polymers 0.000 description 14
- 229950008882 polysorbate Drugs 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000013022 formulation composition Substances 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- -1 heterocyclic amines Chemical class 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 description 4
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000007963 capsule composition Substances 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 229940057948 magnesium stearate Drugs 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000009094 second-line therapy Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 241000237858 Gastropoda Species 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- SPTSIOTYTJZTOG-UHFFFAOYSA-N acetic acid;octadecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O SPTSIOTYTJZTOG-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 208000017760 chronic graft versus host disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960005168 croscarmellose Drugs 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- SFCPXHKCMRZQAC-UHFFFAOYSA-N 2,3-dihydroxypropyl benzoate Chemical compound OCC(O)COC(=O)C1=CC=CC=C1 SFCPXHKCMRZQAC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000003975 aryl alkyl amines Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 229960002366 magnesium silicate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 description 1
- 229940080352 sodium stearoyl lactylate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- the invention relates to stable oral dosage forms of ibrutinib as an active ingredient and, in particular, oral dosage forms comprising ibrutinib and acidifying agent.
- Ibrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to the inhibition of BTK enzymatic activity, thus blocking B-cell receptor signaling, which drives B-cells into apoptosis and/or disrupts cell migration and adherence to protective tumor microenvironments.
- BTK tyrosine kinase
- ibrutinib is approved to treat a variety of blood cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom’s macroglobulinemia and marginal zone lymphoma, as both a first and second line therapy. Ibrutinib is also indicated as a second line therapy for the treatment of chronic graft versus host disease.
- the active drug substance is practically insoluble in aqueous solutions of pH 4.5-8, and only slightly soluble in HC1 at pH 1.2.
- ibrutinib is classified as a BCS Class 2 compound (low solubility and high permeability) which presents a challenge in developing orally bioavailable formulations.
- the IMBRUVICA ® capsule formulation comprises ibrutinib, croscarmellose sodium, microcrystalline cellulose , magnesium stearate and sodium lauryl sulfate encapsulated in a hard gelatin capsule.
- the IMBRUVICA ® tablet formulation comprises ibrutinib, colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone and sodium lauryl sulfate with a film coating.
- ibrutinib that include an acidifying agent such as tartaric acid or citric acid.
- the dosage forms may further include a binder such as sodium alginate.
- the inclusion of the acidifying agent is believed to make the microenvironment more acidic, thereby enhancing the dissolution profile of the drug.
- a first aspect of the invention is an oral dosage form comprising ibrutinib and an acidifying agent.
- the acidifying agent is present in an amount of from about 0.5 to about 5.0 weight percent.
- the acidifying agent is present in an amount of from about 1.0 to about 3.0 weight percent.
- the acidifying agent is selected from the group consisting of tartaric acid and citric acid.
- the acidifying agent is tartaric acid.
- the dosage from further comprises a binder.
- the binder is present in an amount of from about 0.5 to about 10.0 weight percent.
- the binder is present in an amount of from about 1.0 to about 5.0 weight percent.
- the binder comprises sodium alginate.
- the ibrutinib has a particle size having a d9o of from about 75 to about 105 microns.
- the ibrutinib is Form I ibrutinib.
- the oral dosage form is a capsule.
- the oral dosage form releases about 70% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles at 75 rpm.
- the oral dosage form releases about 90% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles at 75 rpm.
- the oral dosage form releases about 90% or more of the ibrutinib within about 30 minutes when tested in 900 mL of 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles at 75 rpm.
- the oral dosage form releases about 70% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 0.1 N HC1, paddles at 50 rpm.
- the oral dosage form releases about 90% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 0.1 N HC1, paddles at 50 rpm.
- the oral dosage form releases about 90% or more of the ibrutinib within about 30 minutes when tested in 900 mL of 0.1 N HC1, paddles at 50 rpm.
- the first aspect is a method of treating a cancer by administering to a patient in need thereof the oral dosage form of the first aspect.
- the method of treating cancer is a method of treating a blood cancer by administering to a patient in need thereof the oral dosage form of the first aspect.
- the method of treating cancer is a method of treating a blood cancer selected from the group consisting of mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom’s macroglobulinemia and marginal zone lymphoma by administering to a patient in need thereof the oral dosage form of the first aspect.
- the first aspect is a method of treating a graft versus host disease by administering to a patient in need thereof the oral dosage form of the first aspect.
- an oral dosage form comprising ibrutinib, an acidifying agent present in an amount of about 1.0 to about 5.0 weight percent and a binder present in an amount of from about 1.0 to about 10 weight percent.
- the acidifying agent is selected from tartaric acid and citric acid and the binder is sodium alginate.
- the oral dosage form further comprises a surfactant, a lubricant, a filler, and a disintegrant.
- the method of treating cancer is a method of treating a blood cancer by administering to a patient in need thereof the oral dosage form of the second aspect.
- the method of treating cancer is a method of treating a blood cancer selected from the group consisting of mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom’s macroglobulinemia and marginal zone lymphoma by administering to a patient in need thereof the oral dosage form of the second aspect.
- the second aspect is a method of treating a graft versus host disease by administering to a patient in need thereof the oral dosage form of the second aspect.
- a third aspect of the disclosure is an oral dosage form consisting essentially of ibrutinib, an acidifying agent, a binder, a surfactant, a lubricant, a filler, and a disintegrant.
- the acidifying agent is present in an amount of from about 1.0 weight percent to about 3.0 weight percent.
- the oral dosage form consists essentially of, or consists of, ibrutinib, tartaric acid or citric acid, sodium alginate, sodium lauryl sulfate, magnesium stearate, a microcrystalline cellulose and croscarmellose sodium.
- tartaric acid or citric acid is present in an amount of from about 1.0 to about 3.0 weight percent.
- sodium alginate is present in an amount of from about 1.0 to about 5.0 weight percent.
- the oral dosage form releases about 70% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles at 75 rpm.
- the oral dosage form releases about 90% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles at 75 rpm.
- the oral dosage form releases about 90% or more of the ibrutinib within about 30 minutes when tested in 900 mL of 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles at 75 rpm [0044] In another example of the third aspect, the oral dosage form releases about 70% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 0.1 N HC1, paddles at 50 rpm. [0045] In still another example of the third aspect, the oral dosage form releases about 70% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 0.1 N HC1, paddles at 50 rpm.
- the oral dosage form releases about 90% or more of the ibrutinib within about 30 minutes when tested in 900 mL of 0.1 N HC1, paddles at 50 rpm.
- the third aspect is a method of treating a cancer by administering to a patient in need thereof the oral dosage form of the third aspect.
- the method of treating cancer is a method of treating a blood cancer by administering to a patient in need thereof the oral dosage form of the third aspect.
- the method of treating cancer is a method of treating a blood cancer selected from the group consisting of mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom’s macroglobulinemia and marginal zone lymphoma by administering to a patient in need thereof the oral dosage form of the third aspect.
- the third aspect is a method of treating a graft versus host disease by administering to a patient in need thereof the oral dosage form of the third aspect.
- the term “about” means that amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact, but may be approximate and/or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors.
- the term “about” is used in describing a value or an end-point of a range, the disclosure should be understood to include the specific value or end-point referred to.
- weight percent is a relative measure of the amount of one excipient or ingredient relative to the total weight of the dosage form and is based on the total weight of the dosage form.
- Total weight of the dosage form refers to the total weight of the tablet if the dosage form, including any coating included thereon or to the total weight of the capsule fill. To be clear, the total weight of the dosage form when the dosage form is a capsule does not include the weight of the capsule shell or any coating included thereon.
- the present disclosure is directed to oral dosage forms of ibrutinib having good stability and bioavailability compared to commercially available dosage forms.
- the dosage forms of the present disclosure comprise ibrutinib and an acidifying agent, such as tartaric acid or citric acid.
- the dosage forms can further comprise a binder, such as sodium alginate.
- the formulations of ibrutinib of the present disclosure are formulated for oral administration.
- the pharmaceutical formulations described herein include, but are not limited to, tablets, capsules, pills, powders, fast melts and multiparticulate formulations; the dosage forms can be formulated for immediate release, controlled release, delayed release, extended release, pulsatile release or mixed immediate and controlled release.
- compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Such processing methods include conventional dry or wet mixing, dissolving, granulating, milling, encapsulating, or compression processes.
- the oral formulations are made via a standard mixing and blending process.
- pharmaceutical formulations for oral use can be obtained by mixing ibrutinib with one or more solid excipients described herein. The resulting mixture can be compressed into tablets or can be capsulized into hard or soft capsules, such as gelatin capsules.
- the oral formulation can by prepared in push-fit capsules, such as a two-piece capsule made of gelatin, hydroxymethylcellulose (HPMC), starch or the like.
- the capsule formulation can comprise one or more pH adjusting agents, binders, carriers, fillers, lubricants, disintegrants, surfactants, wetting agents, stabilizers, antioxidants, preservatives, colorants, flavorings, and/or other pharmaceutically acceptable excipients used in the art.
- the oral dosage forms described herein may also include a film coating, such as a delayed release coating, which disintegrates upon oral ingestion or upon contact with a biological fluid.
- Ibrutinib is a kinase inhibitor first reported in US Patent No. 7,514,444. Subsequently, a number of polymorphic forms of ibrutinib have been reported, including Forms A, B, C, D, E and F, disclosed in US Patent No. 9,540,382 and Form I in WO 2015/081180, herein incorporated by reference.
- the dosage forms of the present disclosure are suitable for use with any polymorphic form of ibrutinib.
- the ibrutinib for use with the disclosed dosage form is Form I of ibrutinib.
- Ibrutinib can be included in the dosage form in any amount as would be suitable for therapeutic use.
- Ibrutinib is currently approved in the US to treat a variety of blood cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom’s macroglobulinemia and marginal zone lymphoma, as both a first - and second-line therapy. Ibrutinib is also indicated as a second line therapy for the treatment of chronic graft versus host disease. Ibrutinib can be administered sequentially with or concurrently in combination with one or more other chemotherapeutics. Conventional dosing regimens for ibrutinib are known in the art, but the drug is typically administered orally once per day in a dose amount considered to be therapeutic.
- IMBRUVICA ® tablets are currently available in dosage amounts of 140 mg, 280 mg, 420 mg, and 560 mg of active pharmaceutical ingredient per tablet.
- IMBRUVICA ® capsules are currently available in dosage amounts of 70 mg and 140 mg of ibrutinib per capsule.
- the IMBRUVICA ® capsules contain Form A ibrutinib and the inactive ingredients of croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate in a gelatin shell.
- the dosage forms of the present disclosure include a pH adjusting agent.
- the pH adjusting agent can be any pharmaceutically acceptable acid or base.
- Suitable pharmaceutically acceptable acids include both inorganic acids, for example, hydrochloric, sulfuric, phosphoric, diphosphoric, hydrobromic, hydroiodic and nitric acid, as well as organic acids, for example citric, fumaric, maleic, malic, ascorbic, oxalic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid, etc.
- Pharmaceutically acceptable bases can include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g.
- the dosage forms of the present disclosure can include one or more pH adjusting agents, for example, a combination of one, two, three or more suitable acids.
- the dosage form includes a pharmaceutically acceptable acid, in particular, tartaric acid or citric acid.
- the pH adjusting agent can be present in any amount as necessary to affect the pH of the surrounding microenvironment.
- the pH adjusting agent (acid or base) can be present in an amount of about 0.5 to about 10.0 weight percent, for example about 0.5 weight percent, about 1.0 weight percent, about 1.5 weight percent, about 2.5 weight percent, about 3.0 weight percent, about 3.5 weight percent, about 4.0 weight percent, about 4.5 weight percent, about 5.0 weight percent, about 5.5 weight percent, about 6.0 weight percent, about 6.5 weight percent, about 7.0 weight percent, about 7.5 weight percent, about 8.0 weight percent, about 8.5 weight percent, about 9.0 weight percent, about 9.5 weight percent, or about 10.0 weight percent, of the total weight of the dosage form.
- the pH adjusting is a pharmaceutically acceptable acid present in an amount of from about 0.5 to about 5.0 weight percent of the total weight of the dosage form.
- the pH adjusting agent is a pharmaceutically acceptable acid present in an amount of from about 0.5 to about 3.0 weight percent of the total weight of the dosage form.
- the pH adjusting agent is a pharmaceutically acceptable acid present in an amount of from about 1.0 to about 2.0 weight percent of the total weight of the dosage form.
- the pH adjusting agent is citric acid or tartaric acid present in an amount of about 0.5 weight percent, about 1.0 weight percent, about 1.5 weight percent, about 2.5 weight percent, or about 3.0 weight percent of the total weight of the dosage form.
- the pH adjusting agent is tartaric acid present in an amount of about 0.5 to about 3.0 weight percent. In another embodiment, the pH adjusting agent is tartaric acid present in an amount of about 0.5 weight percent of the total weight of the dosage form. In another embodiment, the pH adjusting agent is tartaric acid present in an amount of about 1.0 weight percent. In yet another embodiment, the pH adjusting agent is tartaric acid present in an amount of about 1.5 weight percent. In still another embodiment, the pH adjusting agent is tartaric acid present in an amount of about 2.0 weight percent of the total weight of the dosage form. In another embodiment, the pH adjusting agent is tartaric acid present in an amount of about 2.5 weight percent. In still another embodiment, the pH adjusting agent is tartaric acid present in an amount of about 3.0 weight percent.
- Suitable binders according to the present invention include, e.g., amylose, bentonites, cellulose and cellulose derivatives such as carboxymethylcellulose, methylcellulose, HPMC, HPMCAS, hydroxyethylcellulose, hydroxypropylcellulose, ethylcellulose, and microcrystalline cellulose (MCC), crospovidone, dextrin, gelatin, natural or synthetic gums, magnesium aluminum silicate, microcrystalline dextrose, pregelatinized starch, polyethylene glycol, polysaccharide acids, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, povidone, sodium alginate, starches, sugars (e.g., amylose, bentonites, cellulose and cellulose derivatives such as carboxymethylcellulose, methylcellulose, HPMC, HPMCAS, hydroxyethylcellulose, hydroxypropylcellulose, ethylcellulose, and microcrystalline cellulose (MCC), crospovidone,
- the dosage form includes sodium alginate.
- Binders can be included in the dosage form in any amount useful for holding together the ingredients of the dosage form.
- the amount of binder included in an oral dosage form, and in particular for a capsule dosage form, is typically more than about 20 weight percent based on the total weight of the dosage form, e.g. 20 to 70 weight percent. It was surprisingly found that the inclusion of a pH adjusting agent in the form of an acid in combination with a lower amount of binder than would be otherwise be expected provided an oral dosage form having an in vitro dissolution profile that is highly similar to that of the brand product.
- the dosage forms according to the present disclosure can include much lower amounts of binder, for example, about 1.0 to about 10.0 weight percent, for example, about 1.0 weight percent, about 1.5 weight percent, about 2.5 weight percent, about 3.0 weight percent, about 3.5 weight percent, about 4.0 weight percent, about 4.5 weight percent, about 5.0 weight percent, about 5.5 weight percent, about 6.0 weight percent, about 6.5 weight percent, about 7.0 weight percent, about 7.5 weight percent, about 8.0 weight percent, about 8.5 weight percent, about 9.0 weight percent, about 9.5 weight percent, or about 10.0 weight percent, of the total weight of the dosage form.
- the dosage forms according to the present disclosure include a binder in an amount of about 1.0 to about 5.0 weight percent.
- the binder is sodium alginate present in an amount of about 1.0 weight percent, about 1.5 weight percent, about 2.5 weight percent, about 3.0 weight percent, about 3.5 weight percent, about 4.0 weight percent, about 4.5 weight percent, or about 5.0 weight percent of the total weight of the dosage form. In one embodiment, the binder is sodium alginate present in an amount of about 3.0 weight percent.
- Suitable carriers for use in the oral dosage forms described herein include, but are not limited to, gelatin, colloidal silicon dioxide, silicified colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerin, magnesium silicate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose acetate stearate (HPMCAS), sucrose, microcrystalline cellulose (MCC), lactose, mannitol and the like.
- the pharmaceutical dosage forms of the present disclosure can comprise from about 1 to about 70 weight percent of a carrier.
- Suitable filling agents, or fillers, for use in the solid dosage forms described herein include, but are not limited to, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, lactose, microcrystalline cellulose (MCC), silicified MCC (e.g.
- ProSolv ® HD90 cellulose powder, dextrose, dextran, starches, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.
- the filler is silicified MCC.
- the pharmaceutical compositions provided herein may contain from about 1 to about 70 weight percent of a filler.
- Suitable disintegrants for use in the solid dosage forms described herein include, but are not limited to, an alginate such as alginic acid or a salt of alginic acid such as sodium alginate, bentonite, a cellulose such as microcrystalline cellulose, methylcellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium carboxymethylcellulose, cross-linked carboxymethylcellulose, or cross-linked croscarmellose, a cross-linked starch such as sodium starch glycolate, a gum, e.g.
- the disintegrating agent is croscarmellose sodium.
- the amount of disintegrant varies depending on the type of formulation.
- the pharmaceutical compositions provided herein may contain, in one example, from about 0.5 to about 15 weight percent or from about 10 to about 15 weight percent of a disintegrant.
- Suitable lubricants or glidants for use in the solid dosage forms described herein include, but are not limited to, stearic acid, calcium hydroxide, talc, corn starch, sodium stearyl fumarate, alkali-metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc, stearic acid, sodium stearates, magnesium stearate, zinc stearate, waxes, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol or a methoxypolyethylene glycol, PEG 4000, PEG 5000, PEG 6000, propylene glycol, sodium oleate, glyceryl behenate, glyceryl palmitostearate, glyceryl benzoate, magnesium or sodium lauryl sulfate, and the like.
- the lubricant is magnesium stearate.
- the pharmaceutical compositions provided herein may
- Suitable diluents for use in the solid dosage forms described herein include, but are not limited to, cellulose and cellulose derivatives (such as microcrystalline cellulose, silicified MCC, microcellulose, etc.), cyclodextrins, polyols (including mannitol, xylitol, and sorbitol), polysaccharides (for example dextrates and maltodextrin), starches, modified starches, sugars (e.g. lactose, sucrose, and dextrose), talc, and the like.
- the amount of diluent varies depending on the type of formulation.
- the pharmaceutical compositions provided herein may contain from about 1.0 to about 70 weight percent of a diluent.
- Suitable surfactants or wetting agents include copolymers of ethylene oxide and propylene oxide, e.g., Pluronic ® (BASF), glyceryl monostearate, magnesium stearate, oleic acid, polaxomers, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, polysorbates, quaternary ammonium compounds (e.g., Polyquat 10 ® ), sodium lauryl sulfate, sodium oleate, sorbitan monolaurate, sorbitan monooleate, triacetin, triethanolamine oleate, vitamin E TPGS and the like.
- the surfactant is sodium lauryl sulfate.
- the pharmaceutical compositions provided herein may contain about 0.1 to about 5 weight percent of a surfactant or wetting agent.
- the ibrutinib dosage forms can include a stabilizer, including but not limited to an antioxidant or a preservative.
- Suitable stabilizers for use in the solid dosage forms described herein include but are not limited to butylated hydroxytoluene (BHT), sodium ascorbate, and tocopherol.
- BHT butylated hydroxytoluene
- the pharmaceutical compositions provided herein may contain about 0.1 to about 5 weight percent of a stabilizer.
- the particle size of the API was selected to obtain the desired dissolution and to ensure smooth processing of the final dosage form to obtain a finished dosage form that meets specifications.
- All capsules were manufacturing via a dry granulation method by slugging followed by capsule filling. Prosolv HD90 and SLS were first sifted using a 500-micron sieve, and then mixed with ibrutinib in a plastic bag. The resulting mixture was passed through a 500-micron sieve. Sodium alginate was sifted into the sifted API mixture, followed by Ac-di-sol ® (croscarmellose sodium), acidifying agent (tartaric acid or citric acid).
- the resulting mixture was sieved and loaded into a Matcon container and mixed. To this mixture was added part of the magnesium stearate and sieved through a 500-micron filter. The prepared powder mix was then prepared into slugs. The resulting slugs were passed through mesh R.25 using a Glatt crushing machine and collected. The resulting mixture was passed through mesh S1.0 using a Glatt crushing machine before being transferred to the Matcon container and mixed. The remaining magnesium stearate was mixed with a small quantity of the premix and the entire mixture combined and mixed to obtain a powder blend. The powder blend was filled into empty gelatin capsules (size 0) using a filling machine.
- FDA drug release medium 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles, 75 rpm, 900 mL
- 0.1 N HC1 paddles, 50 rpm, 900 mL
- a similarity factor (F2) was calculated for each test capsule relative to a Comparative Example, the Comparative Example capsule being the 140 mg RLD product which is branded as IMBRUVICA ® and contains ibrutinib, croscarmellose sodium, microcrystalline cellulose, magnesium stearate and sodium lauryl sulfate encapsulated in a hard gelatin capsule.
- An F2 value closer to 100 indicates performance closer to the brand product, and above 50 is considered “passing”.
- Table 1 Formulation composition for API particle size determination
- Table 7 Formulation composition for acid effect
- Table 8 Percent drug release for acid effect in 3% w/v Polysorbate in phosphate buffer
- Croscarmellose sodium was selected as the disintegrant for the development of the ibrutinib capsules according to the present disclosure, and the dissolution profile was monitored for capsules comprising 10%, 11.8% and 14% by weight.
- the capsules detailed in Table 13 below were prepared as described above and tested in the 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer and in 0.1 N HC1. The results of the dissolution tests are shown in Tables 14 and 15.
- Table 16 Formulation composition for binder variation
- Table 17 Percent drug release for binder amount variation in 3% w/v Polysorbate in phosphate buffer
- SLS Sodium lauryl sulfate
- Magnesium stearate was selected as the lubricant for the development of the ibrutinib capsules. Magnesium stearate levels were tested at 1.5 wt %, 2.0 wt %, and 2.5 wt % (Table 22). The release profile of each capsule was monitored as described above (Tables 23 and 24).
- Table 22 Formulation composition for magnesium stearate amount variation
- Table 23 Percent drug release for magnesium stearate amount variation in 3% w/v Polysorbate in phosphate buffer
- Capsules according to the formulation provided in Table 25 (below) were prepared as described above.
Abstract
Stable and bioavailable oral dosage forms of ibrutinib, the dosage forms comprising ibrutinib and an acidifying agent. The dosage forms can further comprise a binder, such as sodium alginate, a surfactant, a lubricant, a filler and/or a disintegrant. Methods of treating cancers, particularly blood cancers, and graft versus host disease comprising administering to a patient in need thereof a dosage form comprising ibrutinib and an acidifying agent.
Description
ORAL DOSAGE FORMS OF IBRUTINIB
TECHNICAL FIELD
[001] The invention relates to stable oral dosage forms of ibrutinib as an active ingredient and, in particular, oral dosage forms comprising ibrutinib and acidifying agent.
BACKGROUND
[002] Ibrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to the inhibition of BTK enzymatic activity, thus blocking B-cell receptor signaling, which drives B-cells into apoptosis and/or disrupts cell migration and adherence to protective tumor microenvironments. Currently marketed in the US under the trade name IMBRUVICA®, ibrutinib is approved to treat a variety of blood cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom’s macroglobulinemia and marginal zone lymphoma, as both a first and second line therapy. Ibrutinib is also indicated as a second line therapy for the treatment of chronic graft versus host disease.
[003] The structure of ibrutinib is illustrated below, having a chemical name of l-(3R)-3- (4-amino-3-(4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pryimidin-l-yl)prop-2-en-l-one (MW = 440.51).
[004] The active drug substance is practically insoluble in aqueous solutions of pH 4.5-8, and only slightly soluble in HC1 at pH 1.2. Based on the solubility characteristics and in vitro permeability experiments, ibrutinib is classified as a BCS Class 2 compound (low solubility and high permeability) which presents a challenge in developing orally bioavailable formulations. The IMBRUVICA® capsule formulation comprises ibrutinib, croscarmellose sodium, microcrystalline cellulose , magnesium stearate and sodium lauryl sulfate encapsulated in a hard gelatin capsule. The IMBRUVICA® tablet formulation comprises ibrutinib, colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone and sodium lauryl sulfate with a film coating.
[005] There remains a need for stable oral dosage formulations with enhanced bioavailability given the solubility challenges presented by the active ingredient.
SUMMARY
[006] Described herein are oral dosage forms of ibrutinib that include an acidifying agent such as tartaric acid or citric acid. The dosage forms may further include a binder such as sodium alginate. The inclusion of the acidifying agent is believed to make the microenvironment more acidic, thereby enhancing the dissolution profile of the drug.
[007] In a first aspect of the invention is an oral dosage form comprising ibrutinib and an acidifying agent.
[008] In an example of the first aspect, the acidifying agent is present in an amount of from about 0.5 to about 5.0 weight percent.
[009] In another example of the first aspect, the acidifying agent is present in an amount of from about 1.0 to about 3.0 weight percent.
[0010] In yet another example of the first aspect, the acidifying agent is selected from the group consisting of tartaric acid and citric acid.
[0011] In still another example of the first aspect, the acidifying agent is tartaric acid. [0012] In another example of the first aspect, the dosage from further comprises a binder.
[0013] In another example of the first aspect, the binder is present in an amount of from about 0.5 to about 10.0 weight percent.
[0014] In still another example of the first aspect, the binder is present in an amount of from about 1.0 to about 5.0 weight percent.
[0015] In yet another example of the first aspect, the binder comprises sodium alginate.
[0016] In yet another example of the first aspect, the ibrutinib has a particle size having a d9o of from about 75 to about 105 microns.
[0017] In still another example of the first aspect, the ibrutinib is Form I ibrutinib.
[0018] In yet another example of the first aspect, the oral dosage form is a capsule.
[0019] In another example of the first aspect, the oral dosage form releases about 70% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles at 75 rpm.
[0020] In another example of the first aspect, the oral dosage form releases about 90% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles at 75 rpm.
[0021] In another example of the first aspect, the oral dosage form releases about 90% or more of the ibrutinib within about 30 minutes when tested in 900 mL of 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles at 75 rpm.
[0022] In another example of the first aspect, the oral dosage form releases about 70% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 0.1 N HC1, paddles at 50 rpm.
[0023] In another example of the first aspect, the oral dosage form releases about 90% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 0.1 N HC1, paddles at 50 rpm.
[0024] In another example of the first aspect, the oral dosage form releases about 90% or more of the ibrutinib within about 30 minutes when tested in 900 mL of 0.1 N HC1, paddles at 50 rpm.
[0025] In another example of the first aspect is a method of treating a cancer by administering to a patient in need thereof the oral dosage form of the first aspect.
[0026] In still another example of the first aspect, the method of treating cancer is a method of treating a blood cancer by administering to a patient in need thereof the oral dosage form of the first aspect.
[0027] In still another example of the first aspect, the method of treating cancer is a method of treating a blood cancer selected from the group consisting of mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom’s macroglobulinemia and marginal zone lymphoma by administering to a patient in need thereof the oral dosage form of the first aspect.
[0028] In another example of the first aspect is a method of treating a graft versus host disease by administering to a patient in need thereof the oral dosage form of the first aspect. [0029] In a second aspect is an oral dosage form comprising ibrutinib, an acidifying agent present in an amount of about 1.0 to about 5.0 weight percent and a binder present in an amount of from about 1.0 to about 10 weight percent.
[0030] In an example of the second aspect, the acidifying agent is selected from tartaric acid and citric acid and the binder is sodium alginate.
[0031] In another example of the second aspect, the oral dosage form further comprises a surfactant, a lubricant, a filler, and a disintegrant.
[0032] In another example of the second aspect is a method of treating a cancer by administering to a patient in need thereof the oral dosage form of the second aspect.
[0033] In still another example of the second aspect, the method of treating cancer is a method of treating a blood cancer by administering to a patient in need thereof the oral dosage form of the second aspect.
[0034] In still another example of the second aspect, the method of treating cancer is a method of treating a blood cancer selected from the group consisting of mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom’s macroglobulinemia and marginal zone lymphoma by administering to a patient in need thereof the oral dosage form of the second aspect.
[0035] In another example of the second aspect is a method of treating a graft versus host disease by administering to a patient in need thereof the oral dosage form of the second aspect.
[0036] In a third aspect of the disclosure is an oral dosage form consisting essentially of ibrutinib, an acidifying agent, a binder, a surfactant, a lubricant, a filler, and a disintegrant. [0037] In an example of the third aspect, the acidifying agent is present in an amount of from about 1.0 weight percent to about 3.0 weight percent.
[0038] In another example of the third aspect, the oral dosage form consists essentially of, or consists of, ibrutinib, tartaric acid or citric acid, sodium alginate, sodium lauryl sulfate, magnesium stearate, a microcrystalline cellulose and croscarmellose sodium.
[0039] In still another example of the third aspect, tartaric acid or citric acid is present in an amount of from about 1.0 to about 3.0 weight percent.
[0040] In yet another example of the third aspect, sodium alginate is present in an amount of from about 1.0 to about 5.0 weight percent.
[0041] In another example of the third aspect, the oral dosage form releases about 70% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles at 75 rpm.
[0042] In still another example of the third aspect, the oral dosage form releases about 90% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles at 75 rpm.
[0043] In still another example of the third aspect, the oral dosage form releases about 90% or more of the ibrutinib within about 30 minutes when tested in 900 mL of 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles at 75 rpm [0044] In another example of the third aspect, the oral dosage form releases about 70% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 0.1 N HC1, paddles at 50 rpm.
[0045] In still another example of the third aspect, the oral dosage form releases about 70% or more of the ibrutinib within about 45 minutes when tested in 900 mL of 0.1 N HC1, paddles at 50 rpm.
[0046] In another example of the third aspect, the oral dosage form releases about 90% or more of the ibrutinib within about 30 minutes when tested in 900 mL of 0.1 N HC1, paddles at 50 rpm.
[0047] In another example of the third aspect is a method of treating a cancer by administering to a patient in need thereof the oral dosage form of the third aspect.
[0048] In still another example of the third aspect, the method of treating cancer is a method of treating a blood cancer by administering to a patient in need thereof the oral dosage form of the third aspect.
[0049] In still another example of the third aspect, the method of treating cancer is a method of treating a blood cancer selected from the group consisting of mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom’s macroglobulinemia and marginal zone lymphoma by administering to a patient in need thereof the oral dosage form of the third aspect.
[0050] In another example of the third aspect is a method of treating a graft versus host disease by administering to a patient in need thereof the oral dosage form of the third aspect.
DETAILED DESCRIPTION
[0051] As used herein, the term “about” means that amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact, but may be approximate and/or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors. When the term “about” is used in describing a value or an end-point of a range, the disclosure should be understood to include the specific value or end-point referred to. Whether or not a numerical value or end-point of a range in the specification recites “about,” the numerical value or end-point of a range is intended to include two embodiments: one modified by “about,” and one not modified by “about.” It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint and that ranges include both of the endpoints as well as each of the discreet values therein.
[0052] The terms “substantial,” “substantially,” and variations thereof as used herein are intended to note that a described feature is equal or approximately equal to a value or
description. Moreover, “substantially” is intended to denote that two values are equal or approximately equal. In some embodiments, “substantially” may denote values within about 10% of each other, for example within about 5% of each other, or within about 2% of each other.
[0053] It is noted that the terms “substantially” and “about” may be utilized herein to represent the inherent degree of uncertainty that may be attributed to any quantitative comparison, value, measurement, or other representation. These terms are also utilized herein to represent the degree by which a quantitative representation may vary from a stated reference without resulting in a change in the basic function of the subject matter at issue.
[0054] As used herein, “weight percent” is a relative measure of the amount of one excipient or ingredient relative to the total weight of the dosage form and is based on the total weight of the dosage form. “Total weight of the dosage form” refers to the total weight of the tablet if the dosage form, including any coating included thereon or to the total weight of the capsule fill. To be clear, the total weight of the dosage form when the dosage form is a capsule does not include the weight of the capsule shell or any coating included thereon.
[0055] The present disclosure is directed to oral dosage forms of ibrutinib having good stability and bioavailability compared to commercially available dosage forms. In particular, the dosage forms of the present disclosure comprise ibrutinib and an acidifying agent, such as tartaric acid or citric acid. The dosage forms can further comprise a binder, such as sodium alginate.
[0056] The formulations of ibrutinib of the present disclosure are formulated for oral administration. In some examples, the pharmaceutical formulations described herein include, but are not limited to, tablets, capsules, pills, powders, fast melts and multiparticulate formulations; the dosage forms can be formulated for immediate release, controlled release, delayed release, extended release, pulsatile release or mixed immediate and controlled release.
[0057] Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Such processing methods include conventional dry or wet mixing, dissolving, granulating, milling, encapsulating, or compression processes. In one aspect of the disclosure, the oral formulations are made via a standard mixing and blending process. [0058] In one embodiment, pharmaceutical formulations for oral use can be obtained by mixing ibrutinib with one or more solid excipients described herein. The resulting mixture
can be compressed into tablets or can be capsulized into hard or soft capsules, such as gelatin capsules. In one example, the oral formulation can by prepared in push-fit capsules, such as a two-piece capsule made of gelatin, hydroxymethylcellulose (HPMC), starch or the like. In addition to ibrutinib, the capsule formulation can comprise one or more pH adjusting agents, binders, carriers, fillers, lubricants, disintegrants, surfactants, wetting agents, stabilizers, antioxidants, preservatives, colorants, flavorings, and/or other pharmaceutically acceptable excipients used in the art. The oral dosage forms described herein may also include a film coating, such as a delayed release coating, which disintegrates upon oral ingestion or upon contact with a biological fluid.
[0059] Ibrutinib is a kinase inhibitor first reported in US Patent No. 7,514,444. Subsequently, a number of polymorphic forms of ibrutinib have been reported, including Forms A, B, C, D, E and F, disclosed in US Patent No. 9,540,382 and Form I in WO 2015/081180, herein incorporated by reference. The dosage forms of the present disclosure are suitable for use with any polymorphic form of ibrutinib. In one embodiment of the present disclosure, the ibrutinib for use with the disclosed dosage form is Form I of ibrutinib. [0060] Ibrutinib can be included in the dosage form in any amount as would be suitable for therapeutic use. Ibrutinib is currently approved in the US to treat a variety of blood cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom’s macroglobulinemia and marginal zone lymphoma, as both a first - and second-line therapy. Ibrutinib is also indicated as a second line therapy for the treatment of chronic graft versus host disease. Ibrutinib can be administered sequentially with or concurrently in combination with one or more other chemotherapeutics. Conventional dosing regimens for ibrutinib are known in the art, but the drug is typically administered orally once per day in a dose amount considered to be therapeutic. By way of example, IMBRUVICA® tablets are currently available in dosage amounts of 140 mg, 280 mg, 420 mg, and 560 mg of active pharmaceutical ingredient per tablet. IMBRUVICA® capsules are currently available in dosage amounts of 70 mg and 140 mg of ibrutinib per capsule. The IMBRUVICA® capsules contain Form A ibrutinib and the inactive ingredients of croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate in a gelatin shell. [0061] The dosage forms of the present disclosure include a pH adjusting agent. The pH adjusting agent can be any pharmaceutically acceptable acid or base. Suitable pharmaceutically acceptable acids according to the present disclosure include both inorganic acids, for example, hydrochloric, sulfuric, phosphoric, diphosphoric, hydrobromic, hydroiodic and nitric acid, as well as organic acids, for example citric, fumaric, maleic, malic,
ascorbic, oxalic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid, etc. Pharmaceutically acceptable bases can include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases, for example alkyl amines, arylalkyl amines and heterocyclic amines. The dosage forms of the present disclosure can include one or more pH adjusting agents, for example, a combination of one, two, three or more suitable acids. In a preferred example according to the disclosure, the dosage form includes a pharmaceutically acceptable acid, in particular, tartaric acid or citric acid.
[0062] The pH adjusting agent can be present in any amount as necessary to affect the pH of the surrounding microenvironment. In particular, the pH adjusting agent (acid or base) can be present in an amount of about 0.5 to about 10.0 weight percent, for example about 0.5 weight percent, about 1.0 weight percent, about 1.5 weight percent, about 2.5 weight percent, about 3.0 weight percent, about 3.5 weight percent, about 4.0 weight percent, about 4.5 weight percent, about 5.0 weight percent, about 5.5 weight percent, about 6.0 weight percent, about 6.5 weight percent, about 7.0 weight percent, about 7.5 weight percent, about 8.0 weight percent, about 8.5 weight percent, about 9.0 weight percent, about 9.5 weight percent, or about 10.0 weight percent, of the total weight of the dosage form. In one example, the pH adjusting is a pharmaceutically acceptable acid present in an amount of from about 0.5 to about 5.0 weight percent of the total weight of the dosage form. In another example, the pH adjusting agent is a pharmaceutically acceptable acid present in an amount of from about 0.5 to about 3.0 weight percent of the total weight of the dosage form. In another example, the pH adjusting agent is a pharmaceutically acceptable acid present in an amount of from about 1.0 to about 2.0 weight percent of the total weight of the dosage form. In another example, the pH adjusting agent is citric acid or tartaric acid present in an amount of about 0.5 weight percent, about 1.0 weight percent, about 1.5 weight percent, about 2.5 weight percent, or about 3.0 weight percent of the total weight of the dosage form. In one embodiment, the pH adjusting agent is tartaric acid present in an amount of about 0.5 to about 3.0 weight percent. In another embodiment, the pH adjusting agent is tartaric acid present in an amount of about 0.5 weight percent of the total weight of the dosage form. In another embodiment, the pH adjusting agent is tartaric acid present in an amount of about 1.0 weight percent. In yet another embodiment, the pH adjusting agent is tartaric acid present in an amount of about 1.5 weight percent. In still another embodiment, the pH adjusting agent is tartaric acid present in an amount of about 2.0 weight percent of the total weight of the dosage form. In another embodiment, the pH adjusting agent is tartaric acid present in an amount of about 2.5 weight
percent. In still another embodiment, the pH adjusting agent is tartaric acid present in an amount of about 3.0 weight percent.
[0063] Suitable binders according to the present invention include, e.g., amylose, bentonites, cellulose and cellulose derivatives such as carboxymethylcellulose, methylcellulose, HPMC, HPMCAS, hydroxyethylcellulose, hydroxypropylcellulose, ethylcellulose, and microcrystalline cellulose (MCC), crospovidone, dextrin, gelatin, natural or synthetic gums, magnesium aluminum silicate, microcrystalline dextrose, pregelatinized starch, polyethylene glycol, polysaccharide acids, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, povidone, sodium alginate, starches, sugars (e.g. sucrose, glucose, dextrose, molasses, mannitol, sorbitol, xylitol, lactose), tragacanth, waxes, and the like. In one example according to the disclosure, the dosage form includes sodium alginate.
[0064] Binders can be included in the dosage form in any amount useful for holding together the ingredients of the dosage form. The amount of binder included in an oral dosage form, and in particular for a capsule dosage form, is typically more than about 20 weight percent based on the total weight of the dosage form, e.g. 20 to 70 weight percent. It was surprisingly found that the inclusion of a pH adjusting agent in the form of an acid in combination with a lower amount of binder than would be otherwise be expected provided an oral dosage form having an in vitro dissolution profile that is highly similar to that of the brand product. The dosage forms according to the present disclosure can include much lower amounts of binder, for example, about 1.0 to about 10.0 weight percent, for example, about 1.0 weight percent, about 1.5 weight percent, about 2.5 weight percent, about 3.0 weight percent, about 3.5 weight percent, about 4.0 weight percent, about 4.5 weight percent, about 5.0 weight percent, about 5.5 weight percent, about 6.0 weight percent, about 6.5 weight percent, about 7.0 weight percent, about 7.5 weight percent, about 8.0 weight percent, about 8.5 weight percent, about 9.0 weight percent, about 9.5 weight percent, or about 10.0 weight percent, of the total weight of the dosage form. In one embodiment, the dosage forms according to the present disclosure include a binder in an amount of about 1.0 to about 5.0 weight percent. In another example, the binder is sodium alginate present in an amount of about 1.0 weight percent, about 1.5 weight percent, about 2.5 weight percent, about 3.0 weight percent, about 3.5 weight percent, about 4.0 weight percent, about 4.5 weight percent, or about 5.0 weight percent of the total weight of the dosage form. In one embodiment, the binder is sodium alginate present in an amount of about 3.0 weight percent.
[0065] Suitable carriers for use in the oral dosage forms described herein include, but are not limited to, gelatin, colloidal silicon dioxide, silicified colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerin, magnesium silicate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose acetate stearate (HPMCAS), sucrose, microcrystalline cellulose (MCC), lactose, mannitol and the like. The pharmaceutical dosage forms of the present disclosure can comprise from about 1 to about 70 weight percent of a carrier.
[0066] Suitable filling agents, or fillers, for use in the solid dosage forms described herein include, but are not limited to, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, lactose, microcrystalline cellulose (MCC), silicified MCC (e.g. ProSolv® HD90), cellulose powder, dextrose, dextran, starches, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like. In one example of the disclosed formulation, the filler is silicified MCC. The pharmaceutical compositions provided herein may contain from about 1 to about 70 weight percent of a filler.
[0067] Suitable disintegrants for use in the solid dosage forms described herein include, but are not limited to, an alginate such as alginic acid or a salt of alginic acid such as sodium alginate, bentonite, a cellulose such as microcrystalline cellulose, methylcellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium carboxymethylcellulose, cross-linked carboxymethylcellulose, or cross-linked croscarmellose, a cross-linked starch such as sodium starch glycolate, a gum, e.g. agar, guar, or locust bean, magnesium aluminum silicate, natural starches such as corn starch or potato starch, a pregelatinized starch, or sodium starch glycolate, a cross-linked polymer such as crospovidone, a cross-linked polyvinylpyrrolidone, and/or sodium starch glycolate. In one example provided herein, the disintegrating agent is croscarmellose sodium. The amount of disintegrant varies depending on the type of formulation. The pharmaceutical compositions provided herein may contain, in one example, from about 0.5 to about 15 weight percent or from about 10 to about 15 weight percent of a disintegrant.
[0068] Suitable lubricants or glidants for use in the solid dosage forms described herein include, but are not limited to, stearic acid, calcium hydroxide, talc, corn starch, sodium stearyl fumarate, alkali-metal and alkaline earth metal salts, such as aluminum, calcium,
magnesium, zinc, stearic acid, sodium stearates, magnesium stearate, zinc stearate, waxes, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol or a methoxypolyethylene glycol, PEG 4000, PEG 5000, PEG 6000, propylene glycol, sodium oleate, glyceryl behenate, glyceryl palmitostearate, glyceryl benzoate, magnesium or sodium lauryl sulfate, and the like. In some embodiments provided herein, the lubricant is magnesium stearate. The pharmaceutical compositions provided herein may contain about 0.1 to about 5 weight percent of a lubricant.
[0069] Suitable diluents for use in the solid dosage forms described herein include, but are not limited to, cellulose and cellulose derivatives (such as microcrystalline cellulose, silicified MCC, microcellulose, etc.), cyclodextrins, polyols (including mannitol, xylitol, and sorbitol), polysaccharides (for example dextrates and maltodextrin), starches, modified starches, sugars (e.g. lactose, sucrose, and dextrose), talc, and the like. The amount of diluent varies depending on the type of formulation. The pharmaceutical compositions provided herein may contain from about 1.0 to about 70 weight percent of a diluent.
[0070] Suitable surfactants or wetting agents, include copolymers of ethylene oxide and propylene oxide, e.g., Pluronic® (BASF), glyceryl monostearate, magnesium stearate, oleic acid, polaxomers, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, polysorbates, quaternary ammonium compounds (e.g., Polyquat 10®), sodium lauryl sulfate, sodium oleate, sorbitan monolaurate, sorbitan monooleate, triacetin, triethanolamine oleate, vitamin E TPGS and the like. In some embodiments according to the disclosure, the surfactant is sodium lauryl sulfate. The pharmaceutical compositions provided herein may contain about 0.1 to about 5 weight percent of a surfactant or wetting agent.
[0071] According to the disclosure, the ibrutinib dosage forms can include a stabilizer, including but not limited to an antioxidant or a preservative. Suitable stabilizers for use in the solid dosage forms described herein include but are not limited to butylated hydroxytoluene (BHT), sodium ascorbate, and tocopherol. The pharmaceutical compositions provided herein may contain about 0.1 to about 5 weight percent of a stabilizer.
[0072] Examples
[0073] Particle Size Selection
[0074] As ibrutinib has limited solubility in different buffers, the particle size of the API was selected to obtain the desired dissolution and to ensure smooth processing of the final dosage form to obtain a finished dosage form that meets specifications.
[0075] All capsules were manufacturing via a dry granulation method by slugging followed by capsule filling. Prosolv HD90 and SLS were first sifted using a 500-micron sieve, and then mixed with ibrutinib in a plastic bag. The resulting mixture was passed through a 500-micron sieve. Sodium alginate was sifted into the sifted API mixture, followed by Ac-di-sol® (croscarmellose sodium), acidifying agent (tartaric acid or citric acid). The resulting mixture was sieved and loaded into a Matcon container and mixed. To this mixture was added part of the magnesium stearate and sieved through a 500-micron filter. The prepared powder mix was then prepared into slugs. The resulting slugs were passed through mesh R.25 using a Glatt crushing machine and collected. The resulting mixture was passed through mesh S1.0 using a Glatt crushing machine before being transferred to the Matcon container and mixed. The remaining magnesium stearate was mixed with a small quantity of the premix and the entire mixture combined and mixed to obtain a powder blend. The powder blend was filled into empty gelatin capsules (size 0) using a filling machine.
[0076] Particle size was evaluated by testing dissolution profiles of micronized (d9o = 25 microns) and non-micronized (d9o = 75 microns) Form I ibrutinib in a test formulation as detailed in Table 1 below. All of the prepared formulations were evaluated in the recommended FDA drug release medium (3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, pH 6.8, paddles, 75 rpm, 900 mL) as well as in 0.1 N HC1 (paddles, 50 rpm, 900 mL) and compared to a brand IMBRUVICA® 140 mg capsule for similarity. A similarity factor (F2) was calculated for each test capsule relative to a Comparative Example, the Comparative Example capsule being the 140 mg RLD product which is branded as IMBRUVICA® and contains ibrutinib, croscarmellose sodium, microcrystalline cellulose, magnesium stearate and sodium lauryl sulfate encapsulated in a hard gelatin capsule. An F2 value closer to 100 indicates performance closer to the brand product, and above 50 is considered “passing”.
[0078] Table 2: Percent drug release for particle size determination in 3% w/v Polysorbate in phosphate buffer
[0080] As seen in Tables 2 and 3, the formulations with ibrutinib having a particle size of ds>o around 75 microns had dissolution profiles that more closely resembled that of the brand product than did the micronized API with the smaller particle size. The difference between the non-micronized API and the micronized API was more pronounced in the 0.1 N HC1
dissolution medium (F2 of 89 vs. 54, respectively) as compared to the FDA recommended dissolution medium (F2 of 63 vs. 51, respectively). The final API particle size specifications for use with the dosage forms tested herein were ds>o 75-105 microns.
[0081] Excipient Selection [0082] Addition of an Acid
[0083] Since ibrutinib is a basic drug and its solubility higher in an acidic environment (data not shown), addition of an acid to the formulation was contemplated to determine whether it would enhance the dissolution in in vitro testing. Tartaric acid was added to the composition. Without wishing to be bound by theory, it is believed that inclusion of an acid in the oral formulation results in a more acidic microenvironment, thereby improving dissolution and drug release. Capsules comprising 2.0 wt % tartaric acid were prepared and tested for release compared to otherwise identical capsules without the acid as described above. The capsule formulations are detailed in Table 4 below, and the dissolution profiles in Tables 5 and 6.
[0087] From the data in Tables 5 and 6, it can be seen that in both mediums, the capsules including tartaric acid provided for higher F2 values, indicating a more similar release profile to the Comparative Example as compared to the formulation without tartaric acid.
[0088] To test the effect of acid selection, tartaric acid and citric acid were tested to examine the identity of the acidifying agent on the dissolution profile of ibrutinib capsules. Test capsules according to Table 7 below were made and dissolution profiles measured (Tables 8 and 9) as described above.
[0089] Table 7: Formulation composition for acid effect
[0090] Table 8: Percent drug release for acid effect in 3% w/v Polysorbate in phosphate buffer
[0092] Both of the capsules comprising tartaric acid and citric acid resulted in passing F2 values in both dissolution testing mediums, with the tartartic acid-containing capsule performing slightly better in the Polysorbate medium. Thus, tartartic acid was chosen for further development.
[0093] To determine the optimal amount of acid for inclusion into the capsules, the API release profiles of capsules comprising varying amounts of tartaric acid (0 wt. %, 1 wt. %, 2 wt. %, and 3 wt. %) were tested. Test capsules according to Table 10 below were made and dissolution profiles measured (Tables 11 and 12) as described above.
[0095] Table 11 : Percent drug release for variation in amount of acid in 3% w/v Polysorbate in phosphate buffer
[0097] All three formulations comprising tartaric acid resulted in passing F2 values in the FDA recommended medium, with the highest F2 value observed for 2% tartaric acid (68).
[0098] Notably, consistent with the data above, Table 12 demonstrates that the formulation comprising 2 wt % tartaric acid performed significantly better than did the formulation that did not contain any tartaric acid, despite that formulation having a higher amount of disintegrant.
[0099] Disintegrant
[00100] Croscarmellose sodium (CCS) was selected as the disintegrant for the development of the ibrutinib capsules according to the present disclosure, and the dissolution profile was monitored for capsules comprising 10%, 11.8% and 14% by weight. The capsules detailed in Table 13 below were prepared as described above and tested in the 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer and in 0.1 N HC1. The results of the dissolution tests are shown in Tables 14 and 15.
[00102] Table 14: Percent drug release for disintegrant variation in 3% w/v Polysorbate in phosphate buffer
[00104] As seen in Table 14, all three formulations resulted in a passing F2 value for dissolution in the 3% w/v Polysorbate in phosphate buffer. API release in the 0.1 N HC1 solution (Table 15) was most similar to the RLD brand capsules for the test capsules comprising 11.8 wt % CCS, which was also the highest F2 value for dissolution in the FDA recommended Polysorbate solution (F2 = 68).
[00105] Binder
[00106] In order to improve on the release profiles and make them more similar to the brand, addition of a binder to the acid-containing formulation was contemplated in order to slow the release. Sodium alginate was selected as the binder for the development of the ibrutinib capsules for its desirable hard and compact slugs, resulting in granules with good flow properties. Three batches testing varying amounts of sodium alginate were made according to the present disclosure, and the dissolution profile was monitored for capsules comprising 2%, 3%, and 4% by weight. The capsules detailed in Table 16 below were prepared as described above and tested in the 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer and in 0.1 N HC1. The results of the dissolution tests are shown in Tables 17 and 18.
[00108] Table 17: Percent drug release for binder amount variation in 3% w/v Polysorbate in phosphate buffer
[00110] As seen in Tables 17 and 18, the formulations with 2 wt % and 3 wt % sodium alginate show desirable release patterns and gave passing F2 values in both dissolution
mediums. The capsule preparation comprising 3 wt % sodium alginate demonstrated better physical properties compared to the 2 wt % capsules.
[00111] Wetting agent
[00112] Sodium lauryl sulfate (SLS) was selected as the wetting agent for the development of the ibrutinib capsules. SLS levels were tested at 1.2 wt %, 1.4 wt %, and 1.6 wt % SLS (Table 19). The release profile of each capsule was monitored as described above (Tables 20 and 21).
[00114] Table 20: Percent drug release for SLS amount variation in 3% w/v Polysorbate in phosphate buffer
[00115] Table 21 : Percent drug release for SLS amount variation in 0.1 N HC1
[00116] As seen in Tables 20 and 21, all three SLS variations gave passing F2 values in the Polysorbate medium. The capsules comprising 1.4 wt. % SLS provided the highest F2 value (F2 = 62) in O.I N HCl.
[00117] Lubricant
[00118] Magnesium stearate was selected as the lubricant for the development of the ibrutinib capsules. Magnesium stearate levels were tested at 1.5 wt %, 2.0 wt %, and 2.5 wt % (Table 22). The release profile of each capsule was monitored as described above (Tables 23 and 24).
[00119] Table 22: Formulation composition for magnesium stearate amount variation
[00120] Table 23 : Percent drug release for magnesium stearate amount variation in 3% w/v Polysorbate in phosphate buffer
[00121] Table 24: Percent drug release for magnesium stearate amount variation in 0.1 N
[00122] As seen in Tables 23 and 24, while all three magnesium stearate variations gave passing F2 values in the Polysorbate medium, the 2.0 wt % composition gave the most similar release to the brand product (F2 = 62) in the 0.1 N HC1 dissolution medium.
[00123] Stability Studies
[00124] The capsules comprising ibrutinib and tartaric acid according to the present disclosure were tested for stability
[00125] Capsules according to the formulation provided in Table 25 (below) were prepared as described above.
[00127] The stability of the encapsulated API following 3 mo storage at 30 °C/65% RH and 40 °C/75% RH was tested. Under both sets of storage conditions, the API was determined to be greater than 97% pure by HPLC and dissolution studies determined the API to be more than 95% released within 30 minutes (data not shown), well within specifications for the ibrutinib product.
[00128] Many variations and modifications may be made to the above-described embodiments of the disclosure without departing substantially from the spirit and various principles of the disclosure. All such modifications and variations are intended to be included herein within the scope of this disclosure and protected by the following claims.
Claims
1. An oral dosage form comprising ibrutinib and an acidifying agent.
2. The oral dosage form of claim 1, wherein the acidifying agent is present in an amount of from 0.5 to 5.0 weight percent.
3. The oral dosage form of claim 2, wherein the acidifying agent is present in an amount of from 1.0 to 3.0 weight percent.
4. The oral dosage form of any of the preceding claims, wherein the acidifying agent is selected from the group consisting of tartaric acid and citric acid.
5. The oral dosage form of claim 4, wherein the acidifying agent is tartaric acid.
6. The oral dosage form any of the preceding claims, further comprising a binder.
7. The oral dosage form of claim 6, wherein the binder is present in an amount of from 0.5 to 10.0 weight percent.
8. The oral dosage form of claim 7, wherein the binder is present in an amount of from 1.0 to 5.0 weight percent.
9. The oral dosage form of any of claims 6-8, wherein the binder comprises sodium alginate.
10. The oral dosage form of any of the preceding claims, wherein the ibrutinib has a particle size having a ds>o of from 75 to 105 microns.
11. The oral dosage form of any of the preceding claims, wherein the ibrutinib is Form I ibrutinib.
12. The oral dosage form of any of the preceding claims, wherein the oral dosage form is a capsule.
13. The oral dosage form of any of the preceding claims, wherein the oral dosage form releases 70% or more of the ibrutinib within 45 minutes when tested in 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, 900 mL, pH 6.8, paddles at 75 rpm.
14. The oral dosage form of claim 13, wherein the oral dosage form releases 90% or more of the ibrutinib within 45 minutes.
15. The oral dosage form of any of the preceding claims, wherein the oral dosage form releases 70% or more of the ibrutinib within 45 minutes when tested in 0.1 N HC1,
900 mL, paddles at 50 rpm, 900 mL.
16. The oral dosage form of claim 15, wherein the oral dosage form releases 90% or more of the ibrutinib within 45 minutes.
17. A method of treating a cancer by administering to a patient in need thereof the oral dosage form of any of the preceding claims.
18. The method of claim 17, wherein the cancer is a blood cancer.
19. The method of claim 17 or claim 18, wherein the blood cancer is selected from the group consisting of mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom’s macroglobulinemia and marginal zone lymphoma.
20. A method of treating a graft versus host disease by administering to a patient in need thereof the oral dosage form of any of claims 1-16.
21. An oral dosage form comprising ibrutinib, an acidifying agent present in an amount of from 1.0 to 5.0 weight percent and a binder present in an amount of from 1.0 to 10 weight percent.
22. The oral dosage form of claim 21, wherein the acidifying agent is selected from tartaric acid and citric acid, and wherein the binder is sodium alginate.
23. The oral dosage form of claim 21 or 22, further comprising a surfactant, a lubricant, a filler, and a disintegrant.
24. An oral dosage form consisting essentially of ibrutinib, an acidifying agent, a binder, a surfactant, a lubricant, a filler, and a disintegrant.
25. The oral dosage form of claim 24, wherein the acidifying agent is present in an amount of from 1.0 to 3.0 weight percent.
26. The oral dosage form of claim 24, consisting essentially of ibrutinib, tartaric acid or citric acid, sodium alginate, sodium lauryl sulfate, magnesium stearate, a microcrystalline cellulose and croscarmellose sodium.
27. The oral dosage form of claim 26, wherein the tartaric acid or citric acid is present in an amount of from 1.0 to 3.0 weight percent.
28. The oral dosage form of any of claims 24-27, wherein the sodium alginate is present in an amount of from 1.0 to 5.0 weight percent.
29. The oral dosage form of any of claims 24-28, wherein the oral dosage form releases 70% or more of the ibrutinib within 45 minutes when tested in 3.0% w/v Polysorbate 20 in 50 mM phosphate buffer, 900 mL, pH 6.8, paddles at 75 rpm.
30. The oral dosage form of claim 29, wherein the oral dosage form releases 90% or more of the ibrutinib within 45 minutes.
31. The oral dosage form of any of claims 24-30, wherein the oral dosage form releases 70% or more of the ibrutinib within 45 minutes when tested in 0.1 N HC1, 900 mL, paddles at 50 rpm, 900 mL.
32. The oral dosage form of claim 31, wherein the oral dosage form releases 90% or more of the ibrutinib within 45 minutes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/036712 WO2022260667A1 (en) | 2021-06-10 | 2021-06-10 | Oral dosage forms of ibrutinib |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/036712 WO2022260667A1 (en) | 2021-06-10 | 2021-06-10 | Oral dosage forms of ibrutinib |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022260667A1 true WO2022260667A1 (en) | 2022-12-15 |
Family
ID=76731098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/036712 WO2022260667A1 (en) | 2021-06-10 | 2021-06-10 | Oral dosage forms of ibrutinib |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022260667A1 (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7514444B2 (en) | 2006-09-22 | 2009-04-07 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2015081180A1 (en) | 2013-11-27 | 2015-06-04 | Crystal Pharmatech Inc. | Crystalline form i of ibrutinib |
US9540382B2 (en) | 2012-06-04 | 2017-01-10 | Pharmacyclics Llc | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
US20170258729A1 (en) * | 2015-03-03 | 2017-09-14 | Pharmacyclics Llc | Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor |
CN111000806A (en) * | 2018-10-07 | 2020-04-14 | 威海云睿信息科技有限公司 | Ibrutinib tablet composition |
US20200171036A1 (en) * | 2015-04-06 | 2020-06-04 | Janssen Pharmaceutica Nv | Compositions Containing Ibrutinib |
KR20200127888A (en) * | 2019-05-03 | 2020-11-11 | 보로노이 주식회사 | Oral pharmaceutical compositions in the form of solid formulation comprising ibrutinib or a pharmaceutically acceptable salt thereof and processes for preparing the same |
-
2021
- 2021-06-10 WO PCT/US2021/036712 patent/WO2022260667A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7514444B2 (en) | 2006-09-22 | 2009-04-07 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US9540382B2 (en) | 2012-06-04 | 2017-01-10 | Pharmacyclics Llc | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
WO2015081180A1 (en) | 2013-11-27 | 2015-06-04 | Crystal Pharmatech Inc. | Crystalline form i of ibrutinib |
US20170258729A1 (en) * | 2015-03-03 | 2017-09-14 | Pharmacyclics Llc | Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor |
US20200171036A1 (en) * | 2015-04-06 | 2020-06-04 | Janssen Pharmaceutica Nv | Compositions Containing Ibrutinib |
CN111000806A (en) * | 2018-10-07 | 2020-04-14 | 威海云睿信息科技有限公司 | Ibrutinib tablet composition |
KR20200127888A (en) * | 2019-05-03 | 2020-11-11 | 보로노이 주식회사 | Oral pharmaceutical compositions in the form of solid formulation comprising ibrutinib or a pharmaceutically acceptable salt thereof and processes for preparing the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4463875B2 (en) | Pharmaceutical composition | |
AU2003229705B2 (en) | High drug load tablet | |
EP2588086B1 (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate. | |
JP2020180123A (en) | Oral formulations of deferasirox | |
US20230381194A1 (en) | Suspension for oral administration comprising amorphous tolvaptan | |
TW201906611A (en) | Parbsili solid dosage form | |
JP2011516613A (en) | An oral pharmaceutical composition in a solid dispersion, preferably comprising posaconazole and HPMCAS | |
US7163696B2 (en) | Pharmaceutical formulations | |
KR102512868B1 (en) | Solubility and bioavailability enhanced formulation of Olaparib | |
US10888519B2 (en) | Immediate release pharmaceutical composition of iron chelating agents | |
JP5686452B2 (en) | Tablets containing irbesartan | |
US11433072B1 (en) | Oral dosage forms of ibrutinib | |
CN108125918B (en) | Everolimus pharmaceutical composition | |
EP4257119A1 (en) | Olaparib solid dispersion composition with improved stability and bioavailability | |
WO2022260667A1 (en) | Oral dosage forms of ibrutinib | |
CN110603035A (en) | Compositions with improved water solubility and bioavailability | |
US9675549B2 (en) | Tablet containing composite with cyclodextrin | |
KR20180096530A (en) | Immediate-release and sustained-release pharmaceutical preparation comprising Itopride hydrochloride | |
EP4192439A1 (en) | Solid dosage forms of palbociclib | |
CN110613692A (en) | Topiroxostat tablet and preparation method thereof | |
CN109864978B (en) | Sustained-release preparation of 5-methyltetrahydrofolic acid and preparation method thereof | |
US20230092490A1 (en) | Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof | |
CZ2017255A3 (en) | Film-coated Deferasirox tablets | |
CA3150812A1 (en) | Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors | |
AU2010200509A1 (en) | High drug load tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21736895 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: P6003184/2023 Country of ref document: AE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523451844 Country of ref document: SA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |